Project Description



Melinta Therapeutics

300 George Street
Suite 301
New Haven, CT 06511

Phone: 203-624-5606
Fax: 203-624-5627

General Information
Melinta Therapeutics, based on the application of Nobel Prize-winning science, is dedicated to the discovery, development and commercialization of groundbreaking antibiotics to overcome drug-resistant, life-threatening infections. The need for new therapies for drug-resistant infections is widely recognized as one of the most serious public health issues facing the world today. To meet this need, Melinta Therapeutics is rapidly progressing its late-stage investigational antibiotic, delafloxacin, which is currently in Phase 3 development for acute bacterial skin and skin structure infections (ABSSSI). A key initiative at Melinta is to develop a new class of antibiotics designed to overcome the drug-resistant ESKAPE pathogens known to cause serious hospital infections. Melinta Therapeutics is privately held and backed by Vatera Healthcare Partners and Warburg Pincus.

The company is headquartered in New Haven, CT with offices in Lincolnshire, IL at:

Melinta Therapeutics
300 Tri-State International
Suite 272
Lincolnshire, Il 60069

Other Information
Ownership: Private
CT Employees: 45

> Return to BioCT Member Directory